Table 3.
Results of the proportional hazards model for cardiovascular hospitalisation and mortality and cardiovascular hospitalisation (n = 1760) in relation to allopurinol exposure, showing relative hazard with 95% confidence intervals in brackets
| CV hospitalisation (n=566) | Mortality or cardiovascular hospitalisation (n=1002) | |||
| Unadjusted | Adjusted | Unadjusted | Adjusted | |
| Allopurinol exposure | ||||
| Recent low dose v never | 1.64 (1.16 to 2.32)*** | 1.23 (0.86 to 1.76) | 1.41 (1.06 to 1.86)** | 1.14 (0.86 to 1.53) |
| Longstanding low dose v never | 2.64 (1.79 to 3.90)**** | 2.31 (1.55 to 3.46)**** | 2.15 (1.56 to 2.96)**** | 1.71 (1.23 to 2.38)*** |
| Longstanding high dose v never | 1.20 (0.74 to 1.94) | 1.13 (0.69 to 1.86) | 1.05 (0.72 to 1.54) | 0.96 (0.64 to 1.42) |
| Longstanding high dose v longstanding low dose | 0.45 (0.25 to 0.83)** | 0.49 (0.26 to 0.91)** | 0.49 (0.30 to 0.80)*** | 0.56 (0.34 to 0.92)** |
| Loop diuretic dose | ||||
| Medium v low | 1.58 (1.32 to 1.89)**** | 1.32 (1.10 to 1.59)*** | 1.56 (1.37 to 1.79)**** | 1.41 (1.23 to 1.62)**** |
| High v low | 3.09 (2.29 to 4.16)**** | 1.78 (1.28 to 2.47)**** | 2.58 (2.02 to 3.28)**** | 2.04 (1.57 to 2.66)**** |
| Age (+ 10 years) | 1.04 (0.96 to 1.12) | 1.20 (1.09 to 1.31)**** | 1.20 (1.13 to 1.28)**** | 1.27 (1.19 to 1.36)**** |
| Men v women | 1.02 (0.87 to 1.21) | 0.93 (0.78 to 1.11) | 1.12 (0.99 to 1.26)* | 1.14 (1.00 to 1.30)** |
| Social deprivation (+ 1 category) | 1.13 (1.07 to 1.19)**** | 1.12 (1.06 to 1.18)**** | 1.05 (1.01 to 1.09)** | 1.07 (1.03 to 1.12)**** |
| Number of prior MIs (+ 1) | 1.22 (1.13 to 1.32)**** | 1.13 (1.04 to 1.22)*** | 1.09 (1.03 to 1.16)*** | 1.11 (1.04 to 1.18)*** |
| Diabetes | 0.90 (0.67 to 1.22) | 0.79 (0.58 to 1.07) | 0.48 (0.36 to 0.65)**** | 0.48 (0.35 to 0.65)**** |
| History | ||||
| Use of NSAIDs | 1.17 (0.81 to 1.68) | 1.02 (0.70 to 1.48) | 1.51 (1.18 to 1.93)**** | 1.34 (1.04 to 1.72)** |
| Use of thiazides | 1.14 (0.79 to 1.63) | 1.00 (0.69 to 1.45) | 1.14 (0.87 to 1.50) | 1.04 (0.79 to 1.37) |
| Respiratory illness | 1.26 (1.06 to 1.51)*** | 1.07 (0.89 to 1.29) | 1.46 (1.29 to 1.66)**** | 1.24 (1.08 to 1.42)*** |
| Renal disease | 0.70 (0.51 to 0.95) | 0.67 (0.49 to 0.91)** | 1.01 (0.82 to 1.23) | 0.90 (0.74 to 1.10) |
| Hypertension | 1.23 (0.89 to 1.70) | 1.08 (0.78 to 1.51) | 1.26 (0.99 to 1.61)* | 1.20 (0.94 to 1.55) |
| Drugs in concurrent use | ||||
| Aspirin | 1.11 (0.94 to 1.31) | 1.05 (0.88 to 1.25) | 0.83 (0.74 to 0.94)*** | 0.84 (0.74 to 0.96)** |
| Anticoagulants | 1.69 (1.34 to 2.14)**** | 1.30 (1.01 to 1.68)** | 1.22 (1.00 to 1.49) | 1.05 (0.85 to 1.29) |
| ACE inhibitors | 1.92 (1.63 to 2.26)**** | 1.71 (1.41 to 2.07)**** | 1.30 (1.15 to 1.48)**** | 1.19 (1.03 to 1.38)** |
| β Blockers | 0.94 (0.76 to 1.16) | 1.09 (0.87 to 1.36) | 0.69 (0.58 to 0.82)**** | 0.87 (0.73 to 1.05) |
| Nitrates | 1.87 (1.52 to 2.30)**** | 1.65 (1.33 to 2.04)**** | 1.09 (0.95 to 1.25) | 1.09 (0.94 to 1.25) |
| Digoxin | 1.59 (1.33 to 1.90)**** | 1.25 (1.03 to 1.52)** | 1.44 (1.26 to 1.66)**** | 1.13 (0.98 to 1.31) |
| K+ sparing diuretics | 1.02 (0.86 to 1.21) | 1.18 (0.98 to 1.42)* | 0.97 (0.85 to 1.10) | 0.95 (0.83 to 1.09) |
| Antiarrhythmics | 1.85 (1.34 to 2.54)**** | 1.46 (1.05 to 2.03)** | 1.20 (0.90 to 1.61) | 1.03 (0.77 to 1.39) |
*p < 0.1; **p < 0.05; ***p < 0.01; ****p < 0.001.